title: Critical appraisal of the potential use of cannabinoids in cancer management.
abstract: Cannabinoids have been attracting a great deal of interest as potential anticancer agents. Originally derived from the plant Cannabis sativa, there are now a number of endo-, phyto- and synthetic cannabinoids available. This review summarizes the key literature to date around the actions, antitumor activity, and mechanisms of action for this broad range of compounds. Cannabinoids are largely defined by an ability to activate the cannabinoid receptors - CB1 or CB2. The action of the cannabinoids is very dependent on the exact ligand tested, the dose, and the duration of exposure. Some cannabinoids, synthetic or plant-derived, show potential as therapeutic agents, and evidence across a range of cancers and evidence in vitro and in vivo is starting to be accumulated. Studies have now been conducted in a wide range of cell lines, including glioma, breast, prostate, endothelial, liver, and lung. This work is complemented by an increasing body of evidence from in vivo models. However, many of these results remain contradictory, an issue that is not currently able to be resolved through current knowledge of mechanisms of action. While there is a developing understanding of potential mechanisms of action, with the extracellular signal-regulated kinase pathway emerging as a critical signaling juncture in combination with an important role for ceramide and lipid signaling, the relative importance of each pathway is yet to be determined. The interplay between the intracellular pathways of autophagy versus apoptosis is a recent development that is discussed. Overall, there is still a great deal of conflicting evidence around the future utility of the cannabinoids, natural or synthetic, as therapeutic agents.
authors.affiliation: Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.
authors.forename: Belinda J
authors.initials: BJ
authors.lastname: Cridge
authors.forename: Rhonda J
authors.initials: RJ
authors.lastname: Rosengren
keywords: JWH-133; WIN-55,212-2; cancer; cannabinoid; endocannabinoid; tetrahydrocannabinol
references.citation: Cancer Gene Ther. 2004 Jan;11(1):73-80
references.pmid: 14681728
references.citation: Trends Pharmacol Sci. 1992 May;13(5):201-6
references.pmid: 1604713
references.citation: Oncogene. 2008 Jan 10;27(3):339-46
references.pmid: 17621270
references.citation: Semin Cancer Biol. 2011 Nov;21(5):313-21
references.pmid: 22024769
references.citation: Autophagy. 2009 Oct;5(7):1048-9
references.pmid: 19652543
references.citation: FEBS Lett. 2005 Dec 19;579(30):6885-9
references.pmid: 16337199
references.citation: J Neurooncol. 2005 Aug;74(1):31-40
references.pmid: 16078104
references.citation: Prostate. 2003 Jun 15;56(1):1-12
references.pmid: 12746841
references.citation: Cancer Res. 2006 Jul 1;66(13):6748-55
references.pmid: 16818650
references.citation: Blood. 2002 Jul 15;100(2):627-34
references.pmid: 12091357
references.citation: Cancer Res. 2008 Aug 1;68(15):6468-76
references.pmid: 18676872
references.citation: Proc Soc Exp Biol Med. 2000 Oct;225(1):1-8
references.pmid: 10998193
references.citation: Mol Pharmacol. 2006 Sep;70(3):897-908
references.pmid: 16754784
references.citation: Cancer Res. 2004 Mar 15;64(6):1943-50
references.pmid: 15026328
references.citation: J Pharmacol Exp Ther. 1998 Dec;287(3):1038-47
references.pmid: 9864290
references.citation: Cancer Res. 2004 Dec 15;64(24):8826-30
references.pmid: 15604240
references.citation: Prostaglandins Other Lipid Mediat. 2011 Feb;94(1-2):34-43
references.pmid: 21167293
references.citation: Nat Rev Cancer. 2013 Jan;13(1):51-65
references.pmid: 23235911
references.citation: Eur J Neurosci. 2004 Jul;20(2):441-58
references.pmid: 15233753
references.citation: J Natl Cancer Inst. 1975 Sep;55(3):597-602
references.pmid: 1159836
references.citation: FEBS Lett. 2002 Aug 14;525(1-3):164-8
references.pmid: 12163181
references.citation: J Pharmacol Exp Ther. 2001 May;297(2):629-37
references.pmid: 11303052
references.citation: Mol Pharmacol. 1988 Nov;34(5):605-13
references.pmid: 2848184
references.citation: Cell Signal. 2005 Jan;17(1):25-37
references.pmid: 15451022
references.citation: Trends Pharmacol Sci. 2007 Jan;28(1):39-45
references.pmid: 17141334
references.citation: Oncogene. 2004 Oct 14;23(47):7893-7
references.pmid: 15334058
references.citation: Biochem Pharmacol. 2000 Dec 15;60(12):1807-13
references.pmid: 11108795
references.citation: Mol Pharmacol. 2009 Jan;75(1):158-65
references.pmid: 18838481
references.citation: Science. 1989 Feb 17;243(4893):947-50
references.pmid: 2465572
references.citation: J Clin Endocrinol Metab. 2001 Jun;86(6):2687-96
references.pmid: 11397872
references.citation: Neurobiol Dis. 1998 Dec;5(6 Pt B):432-46
references.pmid: 9974176
references.citation: Curr Opin Cell Biol. 1993 Apr;5(2):274-80
references.pmid: 7685181
references.citation: J Pharmacol Exp Ther. 2001 Dec;299(3):951-9
references.pmid: 11714882
references.citation: Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
references.pmid: 18216770
references.citation: Eur J Pharmacol. 2007 Jun 14;564(1-3):57-65
references.pmid: 17379209
references.citation: Cancer Res. 2004 Aug 15;64(16):5617-23
references.pmid: 15313899
references.citation: Eur J Biochem. 1995 Aug 15;232(1):54-61
references.pmid: 7556170
references.citation: Leuk Res. 2005 Aug;29(8):915-22
references.pmid: 15978942
references.citation: Chem Phys Lipids. 2000 Nov;108(1-2):107-21
references.pmid: 11106785
references.citation: Nature. 1993 Sep 2;365(6441):61-5
references.pmid: 7689702
references.citation: Pharmacol Ther. 2002 Aug;95(2):127-35
references.pmid: 12182960
references.citation: Int J Cancer. 2008 Sep 1;123(5):1025-33
references.pmid: 18546271
references.citation: Hippocampus. 2012 Mar;22(3):643-4
references.pmid: 21538668
references.citation: J Pharmacol Exp Ther. 2004 Mar;308(3):838-45
references.pmid: 14617682
references.citation: Cancer. 2013 Mar 15;119(6):1284
references.pmid: 23233231
references.citation: Mol Cancer. 2010 Jul 22;9:196
references.pmid: 20649976
references.citation: Cancer Immunol Immunother. 2004 Aug;53(8):723-8
references.pmid: 15034673
references.citation: Physiol Behav. 2008 Mar 18;93(4-5):666-70
references.pmid: 18076956
references.citation: Neuropharmacology. 1991 Mar;30(3):237-44
references.pmid: 1649415
references.citation: Science. 1992 Dec 18;258(5090):1946-9
references.pmid: 1470919
references.citation: Physiol Rev. 2003 Jul;83(3):1017-66
references.pmid: 12843414
references.citation: Mol Cancer Res. 2006 Aug;4(8):549-62
references.pmid: 16908594
references.citation: Nat Med. 2000 Mar;6(3):313-9
references.pmid: 10700234
references.citation: Br J Pharmacol. 2007 Nov;152(5):583-93
references.pmid: 17641667
references.citation: Toxicology. 2009 May 2;259(1-2):25-32
references.pmid: 19428940
references.citation: Cancer Metastasis Rev. 2011 Dec;30(3-4):599-612
references.pmid: 22038019
references.citation: J Natl Cancer Inst. 2008 Jan 2;100(1):59-69
references.pmid: 18159069
references.citation: Mol Cancer Ther. 2007 Nov;6(11):2921-7
references.pmid: 18025276
references.citation: Immunobiology. 2010 Aug;215(8):588-97
references.pmid: 20153077
references.citation: Cancer Res. 2008 Jan 15;68(2):339-42
references.pmid: 18199524
references.citation: J Natl Cancer Inst. 1998 Aug 19;90(16):1198-205
references.pmid: 9719080
references.citation: Expert Opin Pharmacother. 2010 Jan;11(1):17-31
references.pmid: 20001426
references.citation: Am J Respir Cell Mol Biol. 2001 Mar;24(3):339-44
references.pmid: 11245634
references.citation: Br J Clin Pharmacol. 2013 Feb;75(2):303-12
references.pmid: 22506672
references.citation: Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):117-31
references.pmid: 19285265
references.citation: J Pharmacol Exp Ther. 2006 Sep;318(3):1375-87
references.pmid: 16728591
references.citation: Nat Rev Cancer. 2012 May 04;12(6):436-44
references.pmid: 22555283
references.citation: Anticancer Res. 2008 Jan-Feb;28(1A):85-9
references.pmid: 18383828
references.citation: Cancer Genet Cytogenet. 2006 Nov;171(1):31-8
references.pmid: 17074588
references.citation: FASEB J. 2003 Mar;17(3):529-31
references.pmid: 12514108
references.citation: Crit Rev Oncol Hematol. 2012 Jul;83(1):1-10
references.pmid: 22019199
references.citation: Cancer Lett. 2009 Nov 18;285(1):6-12
references.pmid: 19442435
references.citation: Mol Cancer Ther. 2009 Nov;8(11):3117-29
references.pmid: 19887554
references.citation: Nat Rev Cancer. 2003 Oct;3(10):745-55
references.pmid: 14570037
references.citation: J Natl Compr Canc Netw. 2012 Apr;10(4):487-92
references.pmid: 22491047
references.citation: Mol Pharmacol. 1999 Dec;56(6):1362-9
references.pmid: 10570066
references.citation: Biochim Biophys Acta. 2013 Oct;1831(10):1573-8
references.pmid: 23567453
references.citation: Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8375-80
references.pmid: 9653194
references.citation: Curr Opin Drug Discov Devel. 2004 Jul;7(4):498-506
references.pmid: 15338959
references.citation: Cell Mol Life Sci. 2008 Mar;65(5):840-50
references.pmid: 18213445
references.citation: Cancer Prev Res (Phila). 2009 Aug;2(8):759-68
references.pmid: 19638490
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):4-15
references.pmid: 22421596
references.citation: Brain Res. 2007 Mar 16;1137(1):161-9
references.pmid: 17239827
references.citation: FEBS Lett. 2005 Sep 12;579(22):5084-8
references.pmid: 16139274
references.citation: FASEB J. 2003 Sep;17(12):1771-3
references.pmid: 12958205
references.citation: Prostaglandins Other Lipid Mediat. 2013 Apr-May;102-103:13-30
references.pmid: 23474290
references.citation: Vitam Horm. 2002;65:225-55
references.pmid: 12481549
references.citation: Br J Pharmacol. 2007 Nov;152(5):567-75
references.pmid: 17906678
references.citation: Biochem Pharmacol. 1998 Nov 15;56(10):1331-8
references.pmid: 9825732
references.citation: J Immunol. 2005 Mar 15;174(6):3281-9
references.pmid: 15749859
references.citation: Exp Cell Res. 2006 Feb 15;312(4):363-73
references.pmid: 16343481
references.citation: J Leukoc Biol. 2003 Oct;74(4):486-96
references.pmid: 12960289
references.citation: Eur J Biochem. 1993 May 15;214(1):173-80
references.pmid: 8508790
references.citation: Eur J Neurosci. 2000 Jun;12(6):2079-86
references.pmid: 10886347
references.citation: Mol Cancer Ther. 2011 Jul;10(7):1161-72
references.pmid: 21566064
references.citation: Eur J Pharmacol. 1970;12(3):382-4
references.pmid: 4322071
references.citation: J Cell Physiol. 2007 May;211(2):495-503
references.pmid: 17192847
references.citation: J Biol Chem. 2005 Oct 28;280(43):35797-806
references.pmid: 16105834
references.citation: Eur J Pharmacol. 2011 Jan 10;650(1):64-71
references.pmid: 20950604
references.citation: Oncogene. 2011 Jan 13;30(2):142-52
references.pmid: 20838378
references.citation: Eur J Pharmacol. 1998 Oct 16;359(1):1-18
references.pmid: 9831287
references.citation: Neuroimmunomodulation. 2007;14(6):281-6
references.pmid: 18287809
references.citation: Cancer Res. 2005 Mar 1;65(5):1635-41
references.pmid: 15753356
references.citation: FASEB J. 2006 Dec;20(14):2633-5
references.pmid: 17065222
references.citation: Exp Cell Res. 2006 Jul 1;312(11):2121-31
references.pmid: 16624285
references.citation: Neurobiol Dis. 1998 Dec;5(6 Pt B):417-31
references.pmid: 9974175
references.citation: Cancer Treat Rev. 2012 Nov;38(7):911-8
references.pmid: 22776349
references.citation: Br J Pharmacol. 2011 Aug;163(7):1447-63
references.pmid: 21410463
references.citation: J Neuroimmune Pharmacol. 2013 Mar;8(1):323-32
references.pmid: 23299999
references.citation: J Biol Chem. 2004 Aug 20;279(34):36013-21
references.pmid: 15210689
references.citation: FEBS Lett. 2003 Dec 18;555(3):561-6
references.pmid: 14675774
references.citation: J Biol Chem. 2004 Dec 3;279(49):51630-46
references.pmid: 15355971
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):869-72
references.pmid: 20160270
references.citation: Br J Pharmacol. 2005 Apr;144(8):1032-6
references.pmid: 15700028
references.citation: Br J Pharmacol. 2006 May;148(2):123-35
references.pmid: 16501583
references.citation: Cancer Res. 2001 Aug 1;61(15):5784-9
references.pmid: 11479216
references.citation: Br J Pharmacol. 1999 Feb;126(3):665-72
references.pmid: 10188977
references.citation: Alcohol Alcohol. 2005 Jan-Feb;40(1):2-14
references.pmid: 15550444
references.citation: J Clin Invest. 2003 Jan;111(1):43-50
references.pmid: 12511587
references.citation: PLoS Biol. 2007 Oct;5(10):e269
references.pmid: 17927447
references.citation: Epidemiol Rev. 1993;15(1):48-65
references.pmid: 8405212
references.citation: Neuropharmacology. 2004;47 Suppl 1:345-58
references.pmid: 15464149
references.citation: J Pharmacol Sci. 2008 Feb;106(2):208-18
references.pmid: 18296861
references.citation: Mol Pharmacol. 2006 Oct;70(4):1298-306
references.pmid: 16822929
references.citation: Nat Rev Cancer. 2002 Aug;2(8):594-604
references.pmid: 12154352
references.citation: Pharmacol Rev. 2010 Dec;62(4):588-631
references.pmid: 21079038
references.citation: Neuropharmacology. 2008 Jan;54(1):235-43
references.pmid: 17675107
references.citation: Br J Pharmacol. 2006 Jan;147 Suppl 1:S163-71
references.pmid: 16402100
references.citation: Biochem J. 2002 Apr 1;363(Pt 1):183-8
references.pmid: 11903061
references.citation: Nature. 1990 Aug 9;346(6284):561-4
references.pmid: 2165569
references.citation: Mol Pharmacol. 2006 Nov;70(5):1612-20
references.pmid: 16936228
references.citation: Cell Mol Life Sci. 2006 Sep;63(17):2057-66
references.pmid: 16909207
references.citation: Endocr Relat Cancer. 2008 Jun;15(2):391-408
references.pmid: 18508995
references.citation: Brain Res. 1999 Mar 20;822(1-2):17-25
references.pmid: 10082879
references.citation: J Mol Endocrinol. 2010 Feb;44(2):75-85
references.pmid: 19620237
references.citation: Cell Signal. 2003 Sep;15(9):851-9
references.pmid: 12834810